Augustyn Alexander, Reed Valerie I, Ahmad Neelofur, Bhutani Manoop S, Bloom Elizabeth S, Bowers John R, Chronowski Gregory M, Das Prajnan, Holliday Emma B, Delclos Marc E, Huey Ryan W, Koay Eugene J, Lee Sunyoung S, Nelson Christopher L, Taniguchi Cullen M, Koong Albert C, Chun Stephen G
Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, United States.
Department of Gastroenterology, Hepatology and Nutrition, Division of Internal Medicine, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, United States.
Clin Transl Radiat Oncol. 2021 Feb 12;27:147-151. doi: 10.1016/j.ctro.2021.02.004. eCollection 2021 Mar.
With increasing interest in stereotactic body radiotherapy (SBRT) for unresectable pancreatic cancer, quality improvement (QI) initiatives to develop integrated clinical workflows are crucial to ensure quality assurance (QA) when introducing this challenging technique into radiation practices.
MATERIALS/METHODS: In 2017, we used the Plan, Do, Study, Act (PDSA) QI methodology to implement a new pancreas SBRT program in an integrated community radiation oncology satellite. A unified integrated information technology infrastructure was used to virtually integrate the planned workflow into the community radiation oncology satellite network (P - Plan/D - Do). This workflow included multiple prospective quality assurance (QA) measures including multidisciplinary evaluation, prospective scrutiny of radiation target delineation, prospective radiation plan evaluation, and monitoring of patient outcomes. Institutional review board approval was obtained to retrospectively study and report outcomes of patients treated in this program (S - Study).
There were 12 consecutive patients identified who were treated in this program from 2017 to 2020 with a median follow-up of 27 months. The median survival was 13 months, median local failure free survival was 12 months and median progression free survival was 6 months from SBRT. There were no acute or late Common Terminology Criteria for Adverse Effects (CTCAE) version 5 toxicities ≥ Grade 3.
We report the successful implementation of a community pancreas SBRT program involving multiple prospective QA measures, providing the groundwork to safely expand access to pancreas SBRT in our community satellite network (A - Act).
随着对不可切除胰腺癌立体定向体部放疗(SBRT)的兴趣日益增加,在将这项具有挑战性的技术引入放射治疗实践时,制定综合临床工作流程的质量改进(QI)举措对于确保质量保证(QA)至关重要。
材料/方法:2017年,我们使用计划-执行-研究-行动(PDSA)QI方法在一个综合社区放射肿瘤卫星中心实施了一项新的胰腺SBRT计划。使用统一的综合信息技术基础设施将计划的工作流程虚拟整合到社区放射肿瘤卫星网络中(P - 计划/D - 执行)。该工作流程包括多项前瞻性质量保证(QA)措施,包括多学科评估、放射靶区勾画的前瞻性审查、放射治疗计划的前瞻性评估以及患者结局监测。获得了机构审查委员会的批准,以回顾性研究和报告该计划中治疗患者的结局(S - 研究)。
2017年至2020年期间,该计划连续治疗了12例患者,中位随访时间为27个月。从SBRT开始计算,中位生存期为13个月;中位无局部失败生存期为12个月;中位无进展生存期为6个月。没有出现急性或晚期不良事件通用术语标准(CTCAE)第5版≥3级毒性反应。
我们报告了一项社区胰腺SBRT计划的成功实施,该计划涉及多项前瞻性QA措施,为在我们的社区卫星网络中安全扩大胰腺SBRT的可及性奠定了基础(A - 行动)。